Geron Co. (NASDAQ:GERN) shares rose 6.3% during mid-day trading on Friday . The stock traded as high as $1.55 and last traded at $1.53, approximately 2,261,000 shares traded hands during trading. An increase of 0% from the average daily volume of 2,260,143 shares. The stock had previously closed at $1.44.

GERN has been the topic of several recent analyst reports. Cantor Fitzgerald initiated coverage on Geron in a research note on Thursday, August 15th. They set an “overweight” rating and a $4.00 target price on the stock. B. Riley lifted their target price on Geron from $3.25 to $4.50 and gave the company a “buy” rating in a research note on Friday, June 28th. BidaskClub downgraded Geron from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. ValuEngine raised Geron from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. Finally, HC Wainwright assumed coverage on Geron in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $4.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $3.90.

The stock has a 50 day simple moving average of $1.42 and a 200-day simple moving average of $1.50. The firm has a market cap of $271.33 million, a P/E ratio of -9.56 and a beta of 2.51.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. Geron had a negative return on equity of 22.33% and a negative net margin of 5,328.80%. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.20 million. As a group, analysts anticipate that Geron Co. will post -0.43 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale increased its stake in Geron by 64.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 41,000 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 16,000 shares during the last quarter. Rudd International Inc. purchased a new position in shares of Geron in the 2nd quarter worth approximately $30,000. Tower Research Capital LLC TRC boosted its holdings in shares of Geron by 482.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 29,801 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 24,684 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Geron by 3.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,080,623 shares of the biopharmaceutical company’s stock worth $1,524,000 after purchasing an additional 31,448 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in shares of Geron by 38.9% in the 2nd quarter. Wells Fargo & Company MN now owns 128,235 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 35,925 shares during the period. 31.16% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile (NASDAQ:GERN)

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.